ArticleCancer cell international2024
Evaluation of functional magnetic resonance APT and DKI imaging for breast cancer.
Article in Cancer cell international, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Multimodal radiomics for early prediction of pathological complete response to neoadjuvant chemotherapy in breast cancer: integration of amide proton transfer weighted imaging in radiomics.BMC medical imaging · 2026Article
- The role of radiomics in predicting the response to neoadjuvant chemotherapy for breast cancer.Cancer biology & medicine · 2026Review
- Differentiation of breast cancer subtypes and correlation with biological status using functional magnetic resonance imaging: comparison with amide proton transfer-weighted imaging and diffusion-weighted imaging.Quantitative imaging in medicine and surgery · 2025Article
- Longitudinal MRI-Driven Multi-Modality Approach for Predicting Pathological Complete Response and B Cell Infiltration in Breast Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
objectiveThis study aimed to compare the performance of amide proton transfer-weighted imaging (APTWI) and diffusion kurtosis imaging (DKI) in differentiating benign from malignant breast lesions, evaluate molecular subtypes of breast cancer, and determine the diagnostic efficacy of the quantitative magnetic resonance imaging (qMRI) parameters in differentiating benign from malignant breast diseases.
methodsThe study included 168 women who underwent breast APTWI and DKI at Yunnan Cancer Hospital between December 2022 and July 2023. The APT signal intensity (SI), apparent kurtosis coefficient (Kapp), non-Gaussian diffusion coefficient (Dapp), and apparent diffusion coefficient (ADC) values were measured before surgery. The differences in the aforementioned qMRI parameters in molecular subtypes of breast cancer were analyzed using one-way analysis of variance. The efficacy of each quantitative parameter in differentiating benign from malignant breast diseases was evaluated using the receiver-operating characteristic curve.
resultsSignificant differences in qMRI parameters were noted between benign and malignant breast lesions. The Kapp (P < .0001) and APT (P < .05) values were higher for malignant tumors than for benign lesions. Conversely, the ADC (P < .0001) and Dapp (P < .0001) values were lower for malignant tumors than for benign lesions. The diagnostic performance was assessed using the area under the curve (AUC) for various parameter combinations. The AUC of Kapp was 0.871, Dapp was 0.872, APT SI was 0.643, DKI + APT was 0.893, DKI + ADC was 0.936, APT + ADC was 0.925, and DKI + APT + ADC was 0.933. Additionally, ADC values (P = .01) demonstrated superior diagnostic performance compared to Kapp (P = .03), Dapp (P = .03), and APT values (P = .06) in distinguishing between different molecular subtypes of breast cancer.
conclusionsAPTWI distinguished benign from malignant breast disease and enhanced the utility of diffusion-weighted MRI. However, it was not superior to DKI and DWI in identifying the molecular subtypes of breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.